Do elevated inflammatory markers indicate higher demand for EPA and DHA?

Systemic inflammation initiates a coordinated biochemical cascade where the body transitionally shifts from initiating an immune response to actively resolving it, relying heavily on omega-3 fatty acids as critical substrates.

Biosynthetic mechanisms

• Lipid mediator class switching: Early acute inflammation triggers phospholipase A2 to liberate EPA and DHA from cell membranes. Pro-inflammatory prostaglandins biochemically signal biosynthetic enzymes—specifically COX-2, 5-LOX, 12-LOX, and 15-LOX—to switch from producing pro-inflammatory eicosanoids to synthesizing specialized pro-resolving mediators (SPMs) such as resolvins, protectins, and maresins.
• Active resolution of inflammation: Rather than acting as passive immunosuppressants, these EPA- and DHA-derived SPMs engage specific receptor pathways to actively terminate inflammation. They restrict further neutrophil recruitment, suppress monocyte-endothelial interactions, and enhance macrophage efferocytosis (the clearance of apoptotic cells) to promote tissue repair.

Clinical implications and physiological demand

• Biomarkers as demand indicators: Elevated levels of high-sensitivity C-reactive protein (hs-CRP), neutrophils, monocytes, and white blood cell (WBC) counts reflect ongoing inflammatory activation. Because SPMs are synthesized "on demand" to resolve this activation, these elevated biomarkers signal a heightened physiological requirement for their omega-3 precursors.
• Substrate insufficiency: Individuals with elevated baseline inflammation frequently experience a state of relative SPM deficiency due to low dietary omega-3 intake. Evidence indicates that cohorts with elevated inflammatory markers derive superior clinical benefits and biomarker improvements when supplied with higher, gram-level doses of EPA and DHA to satisfy this increased metabolic demand.

Bottom line

• Bottom line: Elevated hs-CRP, neutrophils, monocytes, and WBC counts signal active inflammation, representing a state of increased physiological demand for EPA and DHA substrates to fuel the enzymatic production of specialized pro-resolving mediators.